@article{c92e5d6cb8744dd3a2f1b1dad73623d2,
title = "Developing a pathway to support the appropriate, affordable, and widespread use of effective Alzheimer's prevention drugs",
author = "Reiman, {Eric M.} and Soeren Mattke and Kordower, {Jeffrey H.} and Khachaturian, {Zaven S.} and Khachaturian, {Ara S.}",
note = "Funding Information: EMR is a scientific advisor to Alzheon, Aural Analytics, Denali, Green Valley, Retromer Therapeutics, and Vaxxinity; co‐leader of the Alzheimer's Prevention Initiative (API), which includes agreements with and funding from Roche/Genentech, Novartis/Amgen, Lilly/Avid, the National Institute on Aging (NIA), and philanthropy; inventor of a patent assigned to Banner Health related to the accelerated evaluation of Alzheimer's disease (AD) prevention therapies; co‐founder of and shareholder in ALZPath, a startup company involved in advancing the roles of blood‐based biomarkers in AD research, treatment development, and clinical care; and supported by NIA grant P30 AG072980 (Reiman, PI). ",
year = "2022",
month = jan,
doi = "10.1002/alz.12533",
language = "English (US)",
volume = "18",
pages = "7--9",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "1",
}